- Initiation of the pilot study is very good news for InVivo investors.
- We see the Neuro-Spinal Scaffolding as a $500 million device.
- Some of our previous concerns, such as starting the trial, manufacturing delays, and IP have been eased.
- Our primary existing concern is on long-term funding, as the cash position is down to less than six months.
- We are clearly warming back up to the InVivo story. Recent conversations with new CEO, Mark Perrin have certainly helped raise visibility.